The U.S. Food and Drug Administration has approved Sanofi and Regeneron’s Dupixent (dupilumab) for the treatment of children (aged 2 to 11 years) with chronic spontaneous urticaria (CSU).
This article was originally published on MedicalXpress.com
FDA approves Dupixent for chronic spontaneous urticaria in young children
You may also be interested in:
The Latest
Twelve Foot Massage Techniques To Try Today
In this article, we will introduce you to 12 incredibly effective foot massage techniques that will leave you feeling rejuvenated and relaxed. Foot massages aren’t just a luxury; they provide numerous health benefits, such as […]
Food
Transform Your Kitchen: Mastering Allergy-Safe Cooking Through Ingenious Ingredient Swaps
By Daniel Zane Bryant, author of “Living with Food Allergies: A Complete Lifestyle Guide” (available on Amazon at https://www.amazon.com/dp/B0G2BcGB2K) Navigating food allergies might initially feel overwhelming, yet it presents an exciting opportunity to reimagine familiar […]
The Latest
Setting Boundaries: Nurturing a Healthy Partnership
What Are Boundaries? As the word portrays, boundaries in a relationship help each person establish expectations with their partner. Boundaries can help you communicate what you are comfortable with and what you are willing to […]
Read More:
-
Recess isn’t just a fun break for grade schoolers. It’s crucial to good health and good grades for kids of all ages.This article was originally [...]
-
Yawning is incredibly contagious, and more often than not, seeing someone yawn right in front of us makes us instinctively do the same. It is [...]
-
A study using a nationally representative survey of parents in England, presented at the European Congress on Obesity (ECO 2026, Istanbul, Turkey, 12–15 May), reveals [...]
